Healthinvest Partners Ab buys $23,477,048 stake in Anika Therapeutics Inc (ANIK)

Anika Therapeutics Inc (ANIK) : Healthinvest Partners Ab scooped up 111,586 additional shares in Anika Therapeutics Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Apr 19, 2016. The investment management firm now holds a total of 490,331 shares of Anika Therapeutics Inc which is valued at $23,477,048.Anika Therapeutics Inc makes up approximately 9.94% of Healthinvest Partners Ab’s portfolio.

Anika Therapeutics Inc closed down -0.75 points or -1.54% at $47.88 with 1,55,137 shares getting traded on Friday. Post opening the session at $48.66, the shares hit an intraday low of $47.44 and an intraday high of $48.75 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.

Other Hedge Funds, Including , Btim Corp. reduced its stake in ANIK by selling 5,757 shares or 1.15% in the most recent quarter. The Hedge Fund company now holds 493,780 shares of ANIK which is valued at $23,642,186. Anika Therapeutics Inc makes up approx 0.41% of Btim Corp.’s portfolio.New York State Teachers Retirement System boosted its stake in ANIK in the latest quarter, The investment management firm added 800 additional shares and now holds a total of 11,166 shares of Anika Therapeutics Inc which is valued at $534,628.Simplex Trading reduced its stake in ANIK by selling 166 shares or 44.03% in the most recent quarter. The Hedge Fund company now holds 211 shares of ANIK which is valued at $10,208. Capstone Asset Management Co added ANIK to its portfolio by purchasing 4,680 company shares during the most recent quarter which is valued at $226,418. Anika Therapeutics Inc makes up approx 0.01% of Capstone Asset Management Co’s portfolio.Eqis Capital Management reduced its stake in ANIK by selling 5,910 shares or 10.6% in the most recent quarter. The Hedge Fund company now holds 49,825 shares of ANIK which is valued at $2,211,234. Anika Therapeutics Inc makes up approx 0.16% of Eqis Capital Management’s portfolio.

On the company’s financial health, Anika Therapeutics Inc reported $0.72 EPS for the quarter, beating the analyst consensus estimate by $ 0.13 according to the earnings call on Feb 24, 2016. Analyst had a consensus of $0.59. The company had revenue of $30.90 million for the quarter, compared to analysts expectations of $28.19 million. The company’s revenue was up 32.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.51 EPS.

Many Wall Street Analysts have commented on Anika Therapeutics Inc. Company shares were Reiterated by Barrington Research on Feb 26, 2016 to “Outperform”, Firm has raised the Price Target to $ 49 from a previous price target of $45 .

Anika Therapeutics Inc. develops manufactures and commercializes therapeutic products for tissue protection healing and repair. The Company’s products are based on hyaluronic acid (HA) a naturally occurring biocompatible polymer found throughout the body. The Company’s wholly owned subsidiary Anika S.r.l. has about 20 products commercialized primarily in Europe. These products are also all made from HA based on two technologies: HYAFF which is a solid form of HA and ACP gel an autocross-linked polymer of HA. The Company’s technologies for modifying the HA molecule allow product properties to be tailored specifically to therapeutic use. The Company offers therapeutic products from these technologies in the areas of: Orthobiologics Dermal (Advanced wound care and Aesthetic dermatology) Surgical (Anti-adhesion and Ear nose and throat care (ENT)) Ophthalmic and Veterinary.

Leave a Reply

Anika Therapeutics Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Anika Therapeutics Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.